Granulocyte-Macrophage Colony-Stimulating Factor Market Research Report, by Route of Administration (Intravenous Infusion), Application (Fungal Infections, Cut-Burn Wounds), End-User (Hospital, Clinics, Surgical Centre) – Global Forecast Till 2032

TABLE OF CONTENT

Chapter 1. Report Prologue

Chapter 2. Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Chapter 3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary Research

3.4 Market Size Estimation

Chapter 4. Market Dynamics

4.1 Drivers

4.2 Restraints

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Technology Trends & Assessment

Chapter 5. Market Factor Analysis

5.1 Porter’s Five Forces Analysis

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Value Chain Analysis

5.3 Investment Feasibility Analysis

5.4 Pricing Analysis

Chapter 6. Global Granulocyte-Macrophage Colony-Stimulating Factor, by Route of Administration

6.1 Introduction

6.2 Subcutaneous Bolus

6.3 Intravenous Infusion

Chapter 7. Global Granulocyte-Macrophage Colony-Stimulating Factor, by Application

7.1 Introduction

7.2 Fungal Infections

7.3 Skin-Graft

7.4 Cut-Burn Wounds

7.5 Acute Myelogenous Leukemia

7.6 Other

Chapter 8. Global Granulocyte-Macrophage Colony-Stimulating Factor, by End-Users

8.1 Introduction

8.2 Hospitals and Clinics

8.3 Surgical Centers

8.4 Diagnostic Centers

8.5 Research Centers

8.6 Others

Chapter 9. Global Granulocyte-Macrophage Colony-Stimulating Factor, by Region

9.1 Introduction

9.2 America

9.2.1 North America

9.2.1.1 US

9.2.1.2 Canada

9.2.2 South America

9.3 Europe

9.3.1 Western Europe

9.3.1.1 Germany

9.3.1.2 France

9.3.1.3 Italy

9.3.1.4 Spain

9.3.1.5 UK

9.3.1.6 Rest of Western Europe

9.3.2 Eastern Europe

9.4 Asia-Pacific

9.4.1 Japan

9.4.2 China

9.4.3 India

9.4.4 Australia

9.4.5 Republic of Korea

9.4.6 Rest of Asia-Pacific

9.5 Middle East & Africa

9.5.1 United Arab Emirates

9.5.2 Saudi Arabia

9.5.3 Oman

9.5.4 Kuwait

9.5.5 Qatar

9.5.6 Rest of the Middle East & Africa

Chapter 10. Company Landscape

10.1 Introduction

10.2 Market Share Analysis

10.3 Key Development & Strategies

10.3.1 Key Developments

Chapter 11 Company Profiles

11.1 Xconomy, Inc

11.1.1 Company Overview

11.1.2 Type Overview

11.1.3 Financials

11.2.4 Key Developments

11.1.5 SWOT Analysis

11.2 Partner Therapeutics (PTx),

11.2.1 Company Overview

11.2.2 Type Overview

11.2.3 Financial Overview

11.2.4 Key Developments

11.2.5 SWOT Analysis

11.3 Sanofi-Aventis U.S. LLC

11.3.1 Company Overview

11.3.2 Type Overview

11.3.3 Financial Overview

11.3.4 Key Development

11.3.5 SWOT Analysis

11.4 Novartis AG

11.4.1 Company Overview

11.4.2 Type/Business Segment Overview

11.4.3 Financial Overview

11.4.4 Key Development

11.4.5 SWOT Analysis

11.5 Thermo Fisher Scientific

11.5.1 Company Overview

11.5.2 Type Overview

11.5.3 Financial overview

11.5.4 Key Developments

11.5.5 SWOT Analysis

11.6 Merck KGaA

11.6.1 Company Overview

11.6.2 Type Overview

11.6.3 Financial Overview

11.6.4 Key Developments

11.6.5 SWOT Analysis

11.7 Others

Chapter 12 Appendix

LIST OF TABLES

Table 1 Global Granulocyte-Macrophage Colony-Stimulating Factor Industry Synopsis, 2020–2027

Table 2 Global Granulocyte-Macrophage Colony-Stimulating Factor Estimates & Forecast, 2020–2027, (USD Million)

Table 3 Global Granulocyte-Macrophage Colony-Stimulating Factor, by Region, 2020–2027, (USD Million)

Table 4 Global Granulocyte-Macrophage Colony-Stimulating Factor, by Route of Administration, 2020–2027, (USD Million)

Table 5 Global Granulocyte-Macrophage Colony-Stimulating Factor, by Application, 2020–2027, (USD Million)

Table 6 Global Granulocyte-Macrophage Colony-Stimulating Factor, by End-User, 2020–2027, (USD Million)

Table 7 North America: Granulocyte-Macrophage Colony-Stimulating Factor Market, by Route of Administration, 2020–2027, (USD Million)

Table 8 North America: Granulocyte-Macrophage Colony-Stimulating Factor Market, by Application, 2020–2027, (USD Million)

Table 9 North America: Granulocyte-Macrophage Colony-Stimulating Factor Market, by End-User, 2020–2027, (USD Million)

Table 10 US: Granulocyte-Macrophage Colony-Stimulating Factor Market, by Route of Administration, 2020–2027, (USD Million)

Table 11 US: Granulocyte-Macrophage Colony-Stimulating Factor Market, by Application, 2020–2027, (USD Million)

Table 12 US: Granulocyte-Macrophage Colony-Stimulating Factor Market, by End-User, 2020–2027, (USD Million)

Table 13 Canada: Granulocyte-Macrophage Colony-Stimulating Factor Market, by Route of Administration, 2020–2027, (USD Million)

Table 14 Canada: Granulocyte-macrophage colony-stimulating facto Market, by Application, 2020–2027, (USD Million)

Table 15 Canada: Granulocyte-Macrophage Colony-Stimulating Factor Market, by End-User, 2020–2027, (USD Million)

Table 16 South America: Granulocyte-Macrophage Colony-Stimulating Factor Market, by Route of Administration, 2020–2027, (USD Million)

Table 17 South America: Granulocyte-Macrophage Colony-Stimulating Factor Market, by Application, 2020–2027, (USD Million)

Table 18 South America: Granulocyte-Macrophage Colony-Stimulating Factor Market, by End-User, 2020–2027, (USD Million)

Table 19 Europe: Granulocyte-Macrophage Colony-Stimulating Factor Market, Route of Administration, 2020–2027, (USD Million)

Table 20 Europe: Granulocyte-Macrophage Colony-Stimulating Factor Market, by Application, 2020–2027, (USD Million)

Table 21 Europe: Granulocyte-Macrophage Colony-Stimulating Factor Market, by End-User, 2020–2027, (USD Million)

Table 22 Western Europe: Granulocyte-Macrophage Colony-Stimulating Factor Market, by Route of Administration, 2020–2027, (USD Million)

Table 23 Western Europe: Granulocyte-Macrophage Colony-Stimulating Factor Market, by Application, 2020–2027, (USD Million)

Table 24 Western Europe: Granulocyte-Macrophage Colony-Stimulating Factor Market, by End-User, 2020–2027, (USD Million)

Table 25 Eastern Europe: Granulocyte-Macrophage Colony-Stimulating Factor Market, by Route of Administration, 2020–2027, (USD Million)

Table 26 Eastern Europe: Granulocyte-Macrophage Colony-Stimulating Factor Market, by Application, 2020–2027, (USD Million)

Table 27 Eastern Europe: Granulocyte-Macrophage Colony-Stimulating Factor Market, by End-User, 2020–2027, (USD Million)

Table 28 Asia-Pacific: Granulocyte-Macrophage Colony-Stimulating Factor Market, by Route of Administration, 2020–2027, (USD Million)

Table 29 Asia-Pacific: Granulocyte-Macrophage Colony-Stimulating Factor Market, by Application, 2020–2027, (USD Million)

Table 30 Asia-Pacific: Granulocyte-Macrophage Colony-Stimulating Factor Market, by End-User, 2020–2027, (USD Million)

Table 31 Middle East & Africa: Granulocyte-Macrophage Colony-Stimulating Factor Market, by Route of Administration, 2020–2027, (USD Million)

Table 32 Middle East & Africa: Granulocyte-Macrophage Colony-Stimulating Factor Market, by Application, 2020–2027, (USD Million)

Table 33 Middle East & Africa: Granulocyte-Macrophage Colony-Stimulating Factor Market, by End-User, 2020–2027, (USD Million)

LIST OF FIGURES

Figure 1 Research Process

Figure 2 Segmentation for the Global Granulocyte-Macrophage Colony-Stimulating Factor

Figure 3 Market Dynamics for the Global Granulocyte-Macrophage Colony-Stimulating Factor

Figure 4 Global Granulocyte-Macrophage Colony-Stimulating Factor Share, by Route of Administration 2020

Figure 6 Global Granulocyte-Macrophage Colony-Stimulating Factor Share, by Application, 2020

Figure 6 Global Granulocyte-Macrophage Colony-Stimulating Factor Share, by End-User, 2020

Figure 7 Global Granulocyte-Macrophage Colony-Stimulating Factor Share, by Region, 2020

Figure 8 North America Granulocyte-Macrophage Colony-Stimulating Factor Market Share, by Country, 2020

Figure 9 Europe Prescribed Health Apps Share, by Country, 2020

Figure 10 Asia-Pacific Granulocyte-Macrophage Colony-Stimulating Factor Market Share, by Country, 2020

Figure 11 Middle East & Africa Granulocyte-Macrophage Colony-Stimulating Factor Market Share, by Country, 2020

Figure 12 Global Granulocyte-Macrophage Colony-Stimulating Factor: Company Share Analysis, 2020 (%)

Figure 13 Xconomy, Inc: Key Financials

Figure 14 Xconomy, Inc: Segmental Revenue

Figure 15 Xconomy, Inc: Geographical Revenue

Figure 16 Partner Therapeutics (PTx): Key Financials

Figure 17 Partner Therapeutics (PTx): Segmental Revenue

Figure 18 Partner Therapeutics (PTx): Geographical Revenue

Figure 19 Sanofi-Aventis U.S. LLC: Key Financials

Figure 20 Sanofi-Aventis U.S. LLC: Segmental Revenue

Figure 21 Sanofi-Aventis U.S. LLC: Geographical Revenue

Figure 22 Novartis AG: Key Financials

Figure 23 Novartis AG: Segmental Revenue

Figure 24 Novartis AG: Geographical Revenue

Figure 25 Thermo Fisher Scientific: Key Financials

Figure 26 Thermo Fisher Scientific: Segmental Revenue

Figure 27 Thermo Fisher Scientific: Geographical Revenue

Figure 28 Merck KGaA: Key Financials

Figure 29 Merck KGaA: Segmental Revenue

Figure 30 Merck KGaA: Geographical Revenue